Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

SGN-15 enters phase II in advanced ovarian cancer

Aug. 27, 2002

Gleevec granted priority review for first-line use in early CML

Aug. 27, 2002

Oncogene BRAF is mutated in a high proportion of human melanomas

Aug. 27, 2002

Xcytrin to enter new phase III trial in NSCLC patients

Aug. 26, 2002

Novel HDAC inhibitors in early development at Roche

Aug. 23, 2002

STO-609, a potent and selective CaM-KK inhibitor synthesized at Sumitomo

Aug. 23, 2002

ZYC-101a shows potential in the treatment of anal dysplasia

Aug. 22, 2002

R-115777 radiosensitizes previously radioresistant human glioma cells

Aug. 22, 2002

In vitro and in vivo characterization of new KDR inhibitors disclosed by Merck

Aug. 21, 2002

Merck reports novel KDR inhibitors at ACS meeting

Aug. 21, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...